Aura Biosciences (AURA) risk factors
Item 1A of every Aura Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors74 risks3 new2 dropped10 reworded
Auditors issued a going concern opinion highlighting substantial doubt about the company continuing operations for twelve months. The company faces increased risks regarding AI adoption, FDA regulatory interpretations, and market acceptance for bel-sar.
Filed Mar 30, 2026 - FY2024 10-K risk factors73 risks
Aura Biosciences relies heavily on the single product candidate bel-sar for treating early-stage choroidal melanoma and other oncology indications. The company has incurred significant net losses, reporting $86.9 million in 2024 and $76.4 million in 2023. Developing bel-sar requires complex manufacturing, delivery via medical devices like Clearside Biomedical's SCS Microinjector, and extensive regulatory approvals.
Filed Mar 24, 2025